Better Therapeutics, Inc. (BTTX) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 7:30 AM EDTCompleted pivotal trial of BT-001 for type 2 diabetes and reported positive secondary endpoint results after 180 days of treatment
On track to submit de novo classification request for BT-001 with FDA in third quarter of 2022
Completed enrollment in LivVita Liver Study for nonalcoholic fatty liver disease
Appointed Frank Karbe as President and Chief Executive Officer and member of Board of Directors
Company to host conference call and webcast today at 8:30 a.m. ET
SAN FRANCISCO--(BUSINESS... More
